Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-20
2008-05-20
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S376000, C548S226000, C548S183000
Reexamination Certificate
active
07375124
ABSTRACT:
The use is described of derivatives of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with formula (i): in which the substituents have the meanings described in the text, for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidaemias
REFERENCES:
patent: 3262850 (1966-07-01), Jones et al.
patent: 1 422 679 (1976-01-01), None
patent: 03 059875 (2003-07-01), None
Communication dated Jan. 13, 2006 in EP 03 780 669.2—2123 from the European Patent Office.
D. Winegar et al., “Role of peroxisome proliferators-activated receptors in atherosclerosis”, Current Opinion In Cardiovascular, Plumonary and Renal Investigational Drugs, 2000, vol. 2, No. 3, pp. 233-243, XP008029337.
D. Brooks et al., “Design and synthesis of 2-methyl-2-{4-'2-(5-methyl-2-aryloxazol-4-yl)ethoxy!pheonxy }propionic acids: a new class of dual PPARalpha/gamma agonists”, Journal of Medicinal Chemistry, American Chemical Society, vol 44, No. 13, Jun. 21, 2001, pp. 2061-2064, XP002184099.
I. Lalezari et al., “LR-16 A compound with potent effects on the oxygen affinity of hemoglobin on blood cholesterol and on low density lipoprotein”, Proceedings of the national academy of sciences of the United States, vol. 85, No. 16, 1988, pp. 6117-6121, XP001161155.
S. Gronowitz et al., “Potential Hypolipidemic Agents XIX. Synthesis and lipid-lowering properties of the thiophene derivatives related to clofibrate”, ACTA Pharmaceutical Suecica, XX, XX, vol. 15, No. 5, 1978, pp. 361-367, XP01053343.
P. Duriez et al., “Post-Statin Approaches to Hyperlipidaemia”, Expert Opinion on Ivenstigationa Drugs, Ashley Publication Ltd., vol. 7, No. 12, Dec. 1998, pp. 1997-2009, XP000892408.
P.J. Brown et al., “U Ureido-Thiobutyric Acid (GW9578) is a subtype-Selective PPARalpha Agonist with Potent lipid-Lowering ASctivity”, Journal of Medicinal Chemistry, American Chemical Society, vol. 42, No. 19, Apr. 9, 1999, pp. 3785-3788, XP002128791.
M. Guerre-Millo et al., “Peroxisome proliferators-activated receptor alpha activators improve insulin sensitivity and reduce adiposity”, Journal of Biological Chemistry, vol. 275, No. 22, Jun. 2, 2000, pp. 16638-16642, XP002275720.
B. Zhang Bei et al., “New approaches in the treatment of type 2 diabetes”, Current Opinion in Chemical Biology, vol. 4, No. 4, Aug. 2000, pp. 461-467, XP002275721.
R. Hawke et al., “Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity”, Journal of Lipid Research, vol. 38, No. 6, 1997, pp. 1189-1203, XP002275722.
Brunetti Tiziana
Dell'Uomo Natalina
Giannessi Fabio
Milazzo Ferdinando Maria
Pessotto Pompeo
Gembeh Shirley V
Marschel Ardin H.
Nixon & Vanderhye P.C.
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Use of α-phenylthiocarboxylic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of α-phenylthiocarboxylic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of α-phenylthiocarboxylic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2815291